Biology:Avecia
From HandWiki
Revision as of 06:05, 8 August 2021 by imported>WikiGary (fix)
Avecia, a part of Nitto Denko Inc.[1], is a private biotechnology company focused on the development and manufacture of novel medicines using biotechnology techniques. Avecia operates as a contract manufacturing organization (CMO), specializing in oligonucleotide production.[2] Avecia has two United States FDA-audited facilities, one near Boston, MA, and the second in Cincinnati, OH. The combined capacity of these two sites allows Avecia to handle oligonucleotide programs from the pre-clinical through commercial stages. In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.[2]
It was named as one of the top companies in Oligonucleotide Synthesis industry in January 2019.[3]
References
- ↑ http://www.nitto.com www.nitto.com
- ↑ 2.0 2.1 "Nitto Denko Avecia Inc. Acquires the Businesses of Irvine Pharmaceutical Services & Avrio Biopharmaceuticals". Business Wire. 11 October 2016. https://www.businesswire.com/news/home/20161011005765/en/Nitto-Denko-Avecia-Acquires-Businesses-Irvine-Pharmaceutical.
- ↑ "Oligonucleotide Synthesis Market by 2023: Top Players Like GE Healthcare, Nitto Denko Avecia, Genscript, Genedesign, Bio-Synthesis, ATDBio - Press Release - Digital Journal". http://www.digitaljournal.com/pr/4127631.
External links
 |
